精神科合作与授权协议（2019-2025）

"精神病学合作与许可协议" 报告以前所未有的方式，全面深入地展现了全球领先的生物製药公司达成的精神病学交易。

这份经过全面修订和更新的报告详细介绍了2019年至2025年间的569项精神科交易。

本报告提供了交易双方已公布的付款条款。这些数据有助于深入了解付款条款和其他交易条款。

了解潜在合作伙伴协商条款的弹性，有助于深入了解条款谈判过程中可能出现的情况。虽然许多中小企业会寻求详细的付款条款，但魔鬼藏在细节里，尤其是在付款方式和权利转让方面。

本报告全面列出了自 2019 年以来在 "当前协议" 交易和合作资料库中记录的所有合作与许可协议，包括可用的财务条款。报告还包含指向公司及其合作伙伴向美国证券交易委员会提交的实际许可协议文件的线上副本的连结。

本报告的第一章探讨了精神病学领域的交易和商业活动。第一章对报告进行了介绍，第二章分析了精神病学领域的交易趋势。

第三章涵盖了精神科领域已达成交易的财务条款，以及开发阶段的公告。交易按总价值、首付款、里程碑付款和特许权使用费率进行分类。

第四章回顾了在精神科交易中最活跃的 25 家生物製药公司。 对于已向美国证券交易委员会 (SEC) 披露协议的交易，可透过 "当前协议交易与联盟" 资料库在线存取这些协议。

第五章对自 2016 年以来签署和宣布的、且有协议文件可供查阅的精神病学交易进行了全面深入的回顾。每个交易标题均透过网路连结指向实际的线上协议文件，方便读者根据需要轻鬆存取每个协议文件。

第六章依治疗标靶提供了精神科交易的综合目录。

本书还包含大量图表，展示了自 2019 年以来精神病学交易的趋势和活动。

此外，本书还提供了一个以公司名称（A-Z）和技术类型组织的综合交易目录。每个交易标题均透过网路连结指向线上交易记录，并在可用的情况下包含协议文件，方便读者随时存取每个协议文件。

主要优势

精神医学合作研究和授权协议为读者提供以下主要优势：

• 了解 2019 年及以后的交易趋势
• 浏览精神医学合作与许可交易
• 基准分析 - 确定交易市场价值
• 财务条款 - 预付款、里程碑付款、特许权使用费
• 按公司 A-Z、治疗领域和技术类型找到交易目录
• 主要交易价值
• 最活跃的交易撮合者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款与合作伙伴的契合度
• 节省数百小时的研究时间

范围

• 精神病学合作和授权交易旨在帮助全球领先的生物製药公司深入了解精神病学领域的趋势和交易结构。

精神科合作与许可交易包括：

• 生物製药产业精神医学交易趋势
• 合作与授权交易结构概述
• 涵盖製药和生物技术的精神病学交易记录目录
• 主要精神科交易
• 最活跃的精神科许可公司

精神科合作与许可交易清单如下：

• 公司 A-Z
• 交易金额
• 治疗领域
• 技术类型
• 每个交易标题均透过网路连结指向实际的线上交易记录，方便查阅合约文件（如有）。
• 精神病学合作与许可交易
提供对交易记录的全面存取权限，包括合约文件。

合约文件分析有助于进行尽职调查，包括：

• 具体授予或选择哪些权利？
• 合约实际赋予合作伙伴哪些权益？
• 授予了哪些排他性权利？
• 合约的付款结构是什么？
• 如何进行销售和付款审计？
• 合约期限是多久？
• 如何定义合约的关键条款？
• 智慧财产权的处理和所有权是什么？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更，会发生什么事？
• 已达成哪些转许可或分包条款？
• 公司坚持哪些标准条款？
• 哪些标准条款似乎因合作伙伴或交易类型而异？
• 公司主张适用哪种契约法管辖权？

目录

摘要整理

第一章：引言

第二章：精神医学交易趋势

• 引言
• 历年精神医学合作状况
• 按交易类型划分的精神科合作
• 按行业划分的精神科合作
• 依研发阶段划分的精神医学合作
• 按技术类型划分的精神科合作
• 按治疗适应症划分的精神科合作

第三章 精神医学联盟的财务条款

• 引言
• 揭露精神医学联盟的财务条款
• 精神医学联盟的关键价值
• 预付款精神科交易
• 精神科交易中的里程碑付款
• 精神科的特许权使用费率

第四章：精神科护理领域的关键交易与经销商

• 引言
• 精神科联盟中最活跃的机构
• 精神科护理领域最活跃的谈判者名单
• 精神科护理领域价值最高的交易

第五章：精神科合约文件目录

• 引言
• 精神科联盟协议及可用合约

第六章：依治疗目标划分的精神科交易

• 引言
• 依治疗目标划分的精神科交易
• 交易目录
• 交易目录 -精神病交易（按公司、亚利桑那州、2019-2025 年）
• 交易目录 - 精神科交易（依技术类型、2019-2025 年）
• 交易类型定义
• 关于研究公司
• 当前合作伙伴
• 当前协议
• 按目前合作伙伴划分的当前报告标题

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 569 psychiatry deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse psychiatry collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

• Trends in psychiatry dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of psychiatry deal records covering pharmaceutical and biotechnology
• The leading psychiatry deals by value
• Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in psychiatry dealmaking

• 2.1. Introduction
• 2.2. Psychiatry partnering over the years
• 2.3. Psychiatry partnering by deal type
• 2.4. Psychiatry partnering by industry sector
• 2.5. Psychiatry partnering by stage of development
• 2.6. Psychiatry partnering by technology type
• 2.7. Psychiatry partnering by therapeutic indication

Chapter 3 - Financial deal terms for psychiatry partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for psychiatry partnering
• 3.3. Psychiatry partnering headline values
• 3.4. Psychiatry deal upfront payments
• 3.5. Psychiatry deal milestone payments
• 3.6. Psychiatry royalty rates

Chapter 4 - Leading psychiatry deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in psychiatry partnering
• 4.3. List of most active dealmakers in psychiatry
• 4.4. Top psychiatry deals by value

Chapter 5 - Psychiatry contract document directory

• 5.1. Introduction
• 5.2. Psychiatry partnering deals where contract document available

Chapter 6 - Psychiatry dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by psychiatry therapeutic target
• Deal directory
• Deal directory - Psychiatry deals by company A-Z 2019 to 2025
• Deal directory - Psychiatry deals by technology type 2019 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Psychiatry partnering since 2019
• Figure 2: Psychiatry partnering by deal type since 2019
• Figure 3: Psychiatry partnering by industry sector since 2019
• Figure 4: Psychiatry partnering by stage of development since 2019
• Figure 5: Psychiatry partnering by technology type since 2019
• Figure 6: Psychiatry partnering by indication since 2019
• Figure 7: Psychiatry deals with a headline value
• Figure 8: Psychiatry deals with upfront payment values
• Figure 9: Psychiatry deals with milestone payment
• Figure 10: Psychiatry deals with royalty rates
• Figure 11: Active psychiatry dealmaking activity since 2019
• Figure 12: Top psychiatry deals by value since 2019